Objectives: To study the antigenic variations in influenza A/H3N2 viruses circulating in Iran for characterization and phylogenetic relationships to vaccine strains. Methods: RT-PCR, full sequencing of hemagglutinin (HA) and neuraminidase (NA) genes and analysis by sequence handling and phylogenetic programs were done. Results: The HA sequences of 2007 isolates fell within the clade represented by the HA of A/Brisbane/10/07 and characterized by the amino acid changes relative to the HA of A/Wisconsin/67/05, G50E and K140I. The only isolate in 2006 fell within A/Berlin/02/06 with V112I and K173E changes. The 2005 isolates characterized by Y159F, S189N and S227P changes within A/California/07/04. In all isolates we had E190D which is important because this was responsible for the loss of ability of A/H3N2 viruses to bind to chicken red blood cells. There were some substitutions in the antigenic sites of the HA. Similar to other studies, conserved residues for catalytic sites and also framework sites of NA supporting the catalytic residues were detected. We had some changes in the variable regions of the NA head domain. Conclusion: Comparison between Iranian viruses and vaccine strains showed high similarity between them and vaccine strains used in the northern hemisphere.

Keywords:
Influenza A/H3N2 virus, Iranian isolates, Antigenic variations, Surface glycoproteins
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.